Suggested remit: To appraise the clinical and cost effectiveness of tralokinumab within its marketing authorisation for treating moderate to severe atopic dermatitis.
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 3734
Project Team
- Project lead
- Shonagh D'Sylva
Email enquiries
If you have any queries please email TAteam2@nice.org.uk
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- Leo Pharma (tralokinumab)
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Patient carer groups
- National Eczema Society
- Professional groups
- British Association of Dermatologists
- Royal College of Physicians
- Associated public health groups
- None
- Comparator companies
- GlaxoSmithKline (alitretion)
- Novartis Pharmaceuticals (ciclosporin, mycophenolate mofetil)
- Pfizer (methotrexate)
- Sanofi (dupilumab)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 August 2021 | Note added to the project documents |
| 05 August 2021 | Discontinued |
| 04 August 2021 | Schedule affected by COVID-19. We are continuing to face significant capacity challenges and will be delaying the development of tralokinumab for treating moderate to severe atopic dermatitis [ID3734]. This topic will now be considered as part of a multiple technology appraisal [ID3960]. We anticipate that it will be considered by the technology appraisal committee in March 2022. |
| 09 February 2021 | Invitation to participate |
| 05 October 2020 | Note added to the project documents |
| 05 October 2020 | In progress. Topic is in progress |
| 22 July 2020 - 19 August 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual